welcome first quarter financial result conference call operator instruction today presentation opportunity question please note event record would like turn conference senior vice president investor relation please ahead senior vice president investor relation thank operator good afternoon everyone like welcome first quarter financial result conference call afternoon issue press release result press release support slide available website investor section event presentation page speaker today call president chief executive officer chip executive vice president commercial chief financial officer chief medical officer follow prepare remark open line question keep call hour limit question give everyone opportunity participate call today today conference call include forward look statement regard future anticipate event result include company financial outlook anticipate product sale revenue expense potential clinical regulatory milestone include data readout regulatory submission approval actual result development differ materially project imply forward look statement factor cause difference include difficulty forecast sale revenue expense impact relate pandemic uncertainty associate pharmaceutical development regulatory approval process information risk uncertainty face contain caption risk factor include company annual report form year file security exchange commission company subsequent report file turn call president chief executive officer thank good afternoon everyone follow transformational continue make substantial progress evolution global expansion business remain focus investment maximize opportunity value asset fuel ability advance cancer care worldwide look forward share business regulatory development progress call today report record product sale million first quarter represent sequential quarterly growth growth first quarter result reflect rapid adoption strong sale financial strength drive product sale royalty multiple strategic collaboration quarter billion cash investment position expand program advance research development invest business look ahead focus three strategic priority drive continue innovation growth focus pillar ensure organization align empower deliver substantial benefit shareholder employee oncology healthcare provider especially cancer patient first strategic priority maximize global potential three approve medicine robust clinical development program exceptional commercial execution begin remarkable product foundation care multiple express lymphoma indication basis core business commercially available country importantly partner continue pursue additional approval frontline lymphoma peripheral cell lymphoma territory commit maximize patient reach advance clinical development program lymphoma multiple malignancy global success enable continue invest pipeline newer medication next product first class quickly become standard care previously treat metastatic urothelial cancer locally advance metastatic urothelial cancer aggressive disease poor survival high associate healthcare limit treatment option first drug improve survival patient receive platinum chemotherapy checkpoint inhibitor since begin make substantial progress health authority toward expand label secure global approval across share detail activity remark also advance trial design redefine frontline treatment metastatic urothelial cancer patient globally focus combination continue make significant headway explore earlier stage bladder cancer collaboration merck test phase trial muscle invasive bladder cancer patient intend initiate exploratory study muscle invasive bladder cancer third product best class tyrosine kinase inhibitor positive metastatic breast cancer patient without brain metastasis approve country commission approve regulator grant market authorization great significant milestone patient first time approve medicine demonstrate survival benefit positive metastatic breast cancer disease progression follow anti treatment regimen anticipation approval past year establish affiliate country build deep industry experience recently launch please early uptake physician feedback already include treatment guideline give strength clinical evidence expand footprint execute upon another upcoming launch collaborate individual country maximize ability availability patient access addition commercial progress conduct broad political development program design maximize potential include trial evaluate positive breast colorectal gastric cancer mutant tumor second strategic priority advance late stage program toward secure approval product asset vedotin earlier month accept proprietary review seek accelerate approval action date submission comprise data pivotal phase trial present recently publish oncology important development treatment cervical cancer remain lead cause cancer death woman globally position fourth commercial product look expand portfolio together partner prepare launch third strategic priority advance innovative early stage pipeline continue leadership innovation antibody drug conjugate internal investment corporate development opportunity earlier stage pipeline include seven program clinical trial multiple preclinical asset advance toward inaudible proud remarkable progress make grow evolve business asset better meet need cancer patient next turn call chip commercial business provide overview quarterly financial result detail clinical development pipeline progress chip chip executive vice president commercial thank three approve product important first class best class medicine embrace oncologist patient believe brand blockbuster potential continue invest commercial capability ensure maximize opportunity gain future approval label expansion engage customer multiple channel please sale representative able safely return make face face call sale million decline versus pandemic continue impact lymphoma diagnosis early sign recovery despite headwind maintain share frontline indication monitor trend expectation diagnosis rate return historic norm continue message landmark five year progression free survival data frontline lymphoma encourage favorable reaction data receive recent market research physician move first quarter sale million double first quarter please quarterly growth strong launch effort continue focus promote full breadth label locally advance metastatic urothelial cancer marketplace rapidly change confident position year continue growth market evolve sale representative proactive educate healthcare provider label update customer sentiment remain positive risk benefit profile transition first quarter sale million increase last quarter result line expectation give challenge patient dynamic oral continue gain market share patient without brain metastasis provide overall survival benefit patient without brain mets confident continue drive share gain patient utilize product second later line positive breast cancer patient brain mets finally please receive priority review brand place work closely promotional partner ready launch ahead date approve would important drug woman metastatic cervical cancer look forward prove commercial model hand chief financial officer great thank chip thank everyone join call afternoon financial result first quarter reflect significant progress across business briefly summarize financial result quarter line expectation full year total revenue million first quarter include product sale million represent growth first quarter growth product sale drive continue strong uptake since launch royalty revenue first quarter increase million compare million first quarter growth reflect royalty earn increase sale royalty sale collaboration revenue million first quarter compare million first quarter last year discuss give financial guidance collaboration revenue primarily drive progress dependent milestone payment collaborator cause quarterly variation revenue future expect collaboration revenue reflect profit share sale territory sale first quarter increase million include product sale royalty three brand profit share million cash amortization acquire technology expense increase million first quarter reflect continue investment across pipeline drive progress late early stage pipeline expense increase million first quarter reflect commercialization effort relate launch investment support launch first quarter billion cash investment debt position strongly advance plan beyond lastly financial guidance unchanged turn call chief medical officer thank good afternoon everyone happy share today activity approve medicine pipeline program start today reminder accelerate approval unite state metastatic urothelial cancer patient previously receive platinum base chemotherapy checkpoint inhibitor phase trial compare chemotherapy demonstrate clinically meaningful statistically significant reduction risk death among patient receive data present simultaneously publish journal medicine data also submit supplemental real time oncology review program month application accept priority review date application seek convert accelerate approval regular approval integrate label important overall data demonstrate address potential metastatic patient checkpoint inhibitor cisplatin ineligible conduct cohort clinical trial positive data cohort present meet earlier month accept supplemental potentially expand label include population application also review give priority review date abstract include additional follow data cohort report strong data enable substantial regulatory progress outside unite state past month engage eight regulatory authority around world market application currently review include health sign priority review application assign accelerate assessment importantly could shorten time approval lastly continue advance substantial clinical development program include trial could support approval first line metastatic urothelial cancer expect complete enrollment cohort trial cisplatin ineligible patient receive plus year data supportive plan submit supplemental appropriate follow duration response addition continue enroll patient phase global trial include cisplatin eligible ineligible patient evaluate plus compare platinum contain chemotherapy regimen trial support initial data trial result breakthrough therapy designation update durability result long term outcome initial data present move earlier stage bladder cancer phase trial patient muscle invasive disease trial utilize combination keynote trial also call cisplatin eligible patient keynote also call cisplatin ineligible patient additionally continue work bring clinical trial muscle invasive bladder cancer patient complete initial regulatory discussion summary make great progress turn development advance similarly broad clinical program support label expansion breast cancer investigate positive cancer breast cancer evaluate plus first second line metastatic patient trial additionally please report first patient recently compass trial alliance cooperative group evaluate plus high risk adjuvant breast cancer patient cancer track complete enrollment trial trial intend support accelerate approval unite state patient advance surgery positive also advance several exploratory study include combination obsolete platinum base chemotherapy regimen first line cancer basket trial solid tumor include mutation combination within positive breast cancer move excite five year manuscript accept anticipate publication come week result demonstrate robust durable remission patient newly diagnose advance lymphoma receive combination five year free disease progression clinically meaningful important milestone cancer patient journey forward continue invest development several ongoing clinical trial notably phase trial diffuse large cell lymphoma exploratory evaluation plus nivolumab plus frontline advance early stage lymphoma explore combination immunomodulatory agent solid tumor would like turn late stage program vedotin develop collaboration earlier month announce accept seek approval treatment woman recurrent metastatic cervical cancer assign priority review action date believe could make meaningful difference patient high unmet need also recently initiate global phase trial similar population recurrent metastatic cervical cancer patient intend support global regulatory application serve confirmatory trial unite state turn ladiratuzumab vedotin continue work partner merck develop monotherapy combination express solid tumor clinical development program focus optimize dose schedule monotherapy combination breast cancer basket trial also currently patient lung head neck prostate esophageal gastric cancer melanoma across rest pipeline like summarize recent highlight meet early present several preclinical data phase clinical program include show enhance anti tumor activity combine checkpoint inhibitor vedotin base addition describe encourage preclinical data novel vedotin base recently enter clinic also enter clinical trial collaboration pfizer evaluate combination subcutaneous inhibitor combination evaluate part ongoing phase trial advance solid tumor lymphoma lastly complete enrollment clinical trial evaluate part combination regimen treatment pancreatic cancer expect report clinical data trial sometime later year inform next step novel effector function enhance antibody bind close achieve many important milestone make significant progress across pipeline first quarter look forward provide update year progress turn call president chief executive officer thank past year pivotal company position future today deep diverse pipeline multi product commercial portfolio additional potential approval horizon additionally powerful partnership broad geographic footprint substantial financial strength maximize asset early stage pipeline expand portfolio approve medicine solid foundation build stage next phase innovation execution confident ability continue deliver edge innovation medicine make meaningful difference life cancer patient would like thank everyone listen call continue interest operator please open line